Clinical evolution of patients with AF and diabetes mellitus in the COVID-19 pandemic. REFADI Registry
REC: CardioClinics
; 2023.
Article
in English, Spanish
| EMBASE | ID: covidwho-20232947
ABSTRACT
Introduction and objectives:
To analyze the evolution of patients with atrial fibrillation (AF) and diabetes in the mid-term follow-up during the COVID-19 pandemic and to describe its impact on this population. Method(s) Multicenter and prospective registry that included patients with AF and diabetes attended in cardiology clinics. A multivariate analysis was performed to determine the variables associated with the occurrence of clinical events and mortality. Recruitment was performed in February-December 2019. Result(s) The evolution of 633 patients, 96,2% of those included in the REFADI registry with a median follow-up of 835 days was analyzed (mean age 73.8 +/- 8.5 years, 54.3% male, CHA2DS2-VASc 4,34 +/- 1,4, HAS-BLED 2,47 +/- 0,96) were analyzed. The proportion of anticoagulated patients remained constant (95.6% vs 94.5%;P = .24). There was a decrease in the prescription of vitamin K antagonists (from 31.4% to 19.7%;P < .01), and an increase in the use of direct anticoagulants (from 62.0% to 70.3%;P < .01). During the follow-up there was an increase in the prescription of SGLT2 inhibitors (from 20.0% to 25.5%;P < .01) and GLP1 agonists (from 4.2% to 9.1%;P < .01). During this period, 17.2% of patients died, the majority from cardiovascular causes, 6.4% from COVID-19, 2.8% from stroke, and 1.8% from hemorrhage. Older age, lower ejection fraction, lower hemoglobin levels, and especially lower direct anticoagulants prescription were associated with mortality. Conclusion(s) Patients with AF and diabetes have a high thromboembolic risk and a high risk of developing complications, especially of cardiovascular origin.Copyright © 2023 Sociedad Espanola de Cardiologia
Anticoagulation; Atrial fibrillation; covid-19; Diabetes; SGLT2 inhibitors; aged; article; bleeding; cardiology; cerebrovascular accident; CHA2DS2-VASc score; complication; controlled study; coronavirus disease 2019; diabetes mellitus; female; follow up; HAS BLED score; heart ejection fraction; hemoglobin blood level; human; major clinical study; male; mortality; multicenter study; pandemic; prescription; prospective study; thromboembolism; anticoagulant agent; antivitamin K; glucagon like peptide 1 receptor agonist; sodium glucose cotransporter 2 inhibitor
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Language:
English
/
Spanish
Journal:
REC: CardioClinics
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS